Adjunct Lecturer• All courses have been taught both in the traditional classroom as well as via fully online instruction.• Instructor for Advanced Cell Biology I and II. These courses examine cellular structure and function. Topics covered include cell-to-cell signaling involving hormones and receptors, signal transduction pathways, second messenger molecules, cell adhesion, extracellular matrix interactions, cell cycle, programmed cell death, and cell transformation. Besides in depth coverage of the “normal” cell biology, a heavy focus is placed on understanding related pathophysiological states and biotechnological approaches to disease diagnosis and treatment. These courses are part of the core curriculum required for receipt of a Master’s of Science degree in Biotechnology. • Instructor for Biochemistry Course. This is a standard Biochemistry course that I have developed for presentation in the online education environment. The course is taught from the perspective of a Biotechnologist and is part of the core curriculum required for receipt of a Master’s of Science degree in Biotechnology. • Awarded a Certificate for Excellence in Teaching in 2010

Note: In 2018 Panacea Pharmaceuticals changed its name to Sensei Biotherapeutics• Direction of a team of scientists; including Ph.D.’s, associates, technicians and interns • Lead scientist coordinating outside collaborations with both academic and corporate partners • Design and implementation of project development plans for the research department• Budgetary planning and oversight of the company’s research budget• Design, preclinical and clinical development of novel phage-based anti-cancer vaccines • Design and preclinical development of a chimeric antigen receptor T-cell (CAR-T) therapy targeting cancer• Development of cancer immunodiagnostics including immunohistochemistry (IHC), serum based ELISAs and flow cytometry• Director of CLIA-approved laboratory • Transfer of novel assays into a CLIA-approved laboratory environment, including preparation of documentation including SOPs and design and implementation of validation studies• Involved in the preparation of materials for submission to FDA towards the award of a IND for an anti-cancer phage-based vaccine • Design of clinical and non-clinical protocols to support the IND application• Design and implementation of translational studies leading to the successful completion of a Phase I clinical trial• Design of translational studies to support future clinical trials• Scientific review of all materials and correspondence with the agency • Representation of the scientific and technical aspects of the company at several pre-IND meetings• Scientific liaison to upper management including reports to the company’s Board of Directors and Investors • Research reporting through the preparation of reports, peer-reviewed journal articles, meeting abstracts and posters, etc.

Headed research team in the design, preclinical and clinical development of a novel phage-based anti-cancer vaccine, PAN-301, including successful submission of an IND and completion of the phase I clinical trial. Designed and lead translational studies to demonstrate immunogenicity of the vaccine. Lead efforts in the design and preclinical development of antibody-based therapies for cancer, including antibody-drug conjugates (ADCs), radio-immunotherapies and radio-labeled monoclonal antibodies for in vivo imaging of cancer. Supervised the development of a cancer immunodiagnostic using a serum based ELISA format which was utilized to select patients for the phase I clinical trial.Directed a team of scientists; including Ph.D.’s, associates, technicians and interns; coordinated outside collaborations with both academic and corporate partners; served as scientific liaison to upper management including reporting to the company’s Board of Directors and Investors; oversight of the company’s research budget; involved in the preparation of materials for submission to FDA towards the award of an IND and subsequent follow-up; represented the Company at scientific meetings; prepared reports and peer-reviewed publications.

Principal investigator on projects focused on cancer and neurodegenerative disorders; including Stroke, Alzheimer’s disease, and Parkinson’s disease. Cancer programs include both diagnostic and therapeutic approaches with a specific focus on the development of monoclonal antibodies as lead candidates. Involved in all stages of the research; including project development, experimental design, coordination of the research effort, data interpretation and reporting. Management of a team of 12+ scientists; including Ph.D.’s, associates, technicians and interns. Grant and publication preparation. Scientific liaison to upper management and patent counsel. Lead scientist coordinating outside collaborations with both academic and corporate partners. Attendance and presentations at scientific meetings. Formulation and writing of corporate documentation (business plan, supporting material, etc.) and investor presentations. Involved in development of pre-clinical and clinical protocols; including coordination with manufacturing, regulatory and clinical departments and meetings with the FDA.

Principal investigator on projects focused on cancer diagnosis. Worked on the development a platform technology for multiplexing immunohistochemistry and its application development of tissue-based clinical diagnostics. Developed an autoantibody-based blood test for the early detection of lung cancer. Redirected research focus of the company from technology development to clinical application and product development. Transferred a multiplexed autoantibody-based blood test for the early detection of lung cancer (PAULA's Test) from the research lab to the clinical lab including analytical and clinical validation of the test. Commercialized PAULA's Test through an in-house CLIA-approved laboratory. Served as Technical Director of the CLIA certified lab and performed oversight and preparation of all documentation for the Lab Quality System and Quality Manual. Served as scientific liaison to upper management including reports to the company’s Board of Directors and presentations to current and prospective investors as well as to outside collaborators including academic and industry organizations. Designed and implemented project development plans including budgeting for the research department in excess of $2 million per annum. Formulated and authored corporate documentation including business plans, investor presentations, marketing materials etc. Managed and wrote grants to secure both government and private funding. Secured ~4 million dollars in grant funding including a prestigious BRIDGE award from the NCI and through the federal Therapeutic Discovery Project Program.

Lead investigator on projects focused on translational medicine including biomarker discovery and diagnostic development. Ariadne Diagnostics was focused on the development of a tissue-based diagnostic test to predict treatment response to anti-cancer agents, specifically targeted at metastatic colorectal cancer and on the development of diagnostics for neuromuscular and neurodegenerative diseases, including Duchenne's muscular dystrophy. As a co-founder and VP of Research, I lead the day to day operations of the Company, including budgeting, finances, business negotiations and legal issues; authored corporate documentation including business plans, investor presentations, etc.; oversaw grants management and writing including both government and private funding; and designed and implemented all project development plans.

Projects included work in immunology, molecular biology and biochemistry. Work focused on the characterization of the basic biology underlying ubiquitin-dependent protein degradation with a bent towards drug discovery. Responsible for all aspects of the projects including initiation of novel ideas and approaches, detailed written proposals, experimental design and implementation, data analysis and interpretation, and final presentation.